Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BC002
- Development stage
- Phase 3
- Lead developer
- Sichuan Luzhou Buchang Biopharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
BC002 is a biological drug developed by Sichuan Luzhou Buchang Biopharmaceutical, a subsidiary of Buchang Pharma. It is a biosimilar of etanercept, a recombinant human tumor necrosis factor (TNF) receptor-Fc fusion protein. BC002 consists of the extracellular ligand-binding portion of the human 75 kDa (p75) TNF receptor linked to the Fc portion of human IgG1. It functions as a TNF inhibitor by competitively binding to both TNF-alpha and lymphotoxin-alpha (TNF-beta), preventing their interaction with cell-surface TNF receptors and thereby downregulating the inflammatory cascade. The drug is primarily being developed for the treatment of autoimmune and inflammatory conditions, including rheumatoid arthritis and ankylosing spondylitis.
- Other names
- Recombinant human tumor necrosis factor receptor-antibody fusion proteinEtanercept biosimilar注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
02
Targets
LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on BC002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BC002.